Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528335 | 0.87 | GPR6 (0.41) | TRPV1GPR119SLC6A4NOS2FFAR1 | |
| SCHEMBL2529059 | 0.87 | TRPV1 (0.52) | TRPV1GPR119CNR2 | |
| SCHEMBL2531187 | 0.85 | TRPV1 (0.46) | TRPV1CNR2FFAR1 | |
| SCHEMBL2526422 | 0.83 | TRPV1 (0.41) | TRPV1GPR119USP30 | |
| SCHEMBL2524741 | 0.79 | SLC6A4 (0.46) | TRPV1GPR119CNR2SLC6A4NOS2 | |
| SCHEMBL2524371 | 0.77 | SLC6A4 (0.44) | TRPV1SLC6A4NOS2 | |
| SCHEMBL2525496 | 0.77 | SLC6A4 (0.44) | TRPV1SLC6A4NOS2 | |
| SCHEMBL2532224 | 0.76 | TRPV1 (0.43) | TRPV1GPR119CNR2SLC6A4NOS2 | |
| SCHEMBL2530058 | 0.76 | PTGS2 (0.44) | TRPV1SLC6A4NOS2 | |
| SCHEMBL14764910 | 0.76 | AAK1 (0.48) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-8038010-B1 | Single piece edge protector for curved objects | ILLINOIS TOOL WORKS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1940821-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885GPR119 152/4885CNR2 16/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885GPR119 152/4885CNR2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.